These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
344 related articles for article (PubMed ID: 32058001)
1. MRI T Lee H; Baek SY; Kim EJ; Huh GY; Lee JH; Cho H Neuroimage; 2020 May; 211():116625. PubMed ID: 32058001 [TBL] [Abstract][Full Text] [Related]
2. Parkinson's disease-related increase of T2*-weighted hypointensity in substantia nigra pars compacta. Langley J; Huddleston DE; Sedlacik J; Boelmans K; Hu XP Mov Disord; 2017 Mar; 32(3):441-449. PubMed ID: 28004859 [TBL] [Abstract][Full Text] [Related]
3. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Biondetti E; Santin MD; Valabrègue R; Mangone G; Gaurav R; Pyatigorskaya N; Hutchison M; Yahia-Cherif L; Villain N; Habert MO; Arnulf I; Leu-Semenescu S; Dodet P; Vila M; Corvol JC; Vidailhet M; Lehéricy S Brain; 2021 Nov; 144(10):3114-3125. PubMed ID: 33978742 [TBL] [Abstract][Full Text] [Related]
4. Comprehensive MRI quantification of the substantia nigra pars compacta in Parkinson's disease. Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Takahashi K; Yamamoto K; Liu T; Wang Y; Tomiyama N Eur J Radiol; 2018 Dec; 109():48-56. PubMed ID: 30527311 [TBL] [Abstract][Full Text] [Related]
5. T1-weighted MRI shows stage-dependent substantia nigra signal loss in Parkinson's disease. Schwarz ST; Rittman T; Gontu V; Morgan PS; Bajaj N; Auer DP Mov Disord; 2011 Aug; 26(9):1633-8. PubMed ID: 21491489 [TBL] [Abstract][Full Text] [Related]
6. Spatiotemporal changes in substantia nigra neuromelanin content in Parkinson's disease. Biondetti E; Gaurav R; Yahia-Cherif L; Mangone G; Pyatigorskaya N; Valabrègue R; Ewenczyk C; Hutchison M; François C; Arnulf I; Corvol JC; Vidailhet M; Lehéricy S Brain; 2020 Sep; 143(9):2757-2770. PubMed ID: 32856056 [TBL] [Abstract][Full Text] [Related]
7. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease. Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857 [TBL] [Abstract][Full Text] [Related]
8. Comparative Study of MRI Biomarkers in the Substantia Nigra to Discriminate Idiopathic Parkinson Disease. Pyatigorskaya N; Magnin B; Mongin M; Yahia-Cherif L; Valabregue R; Arnaldi D; Ewenczyk C; Poupon C; Vidailhet M; Lehéricy S AJNR Am J Neuroradiol; 2018 Aug; 39(8):1460-1467. PubMed ID: 29954816 [TBL] [Abstract][Full Text] [Related]
9. In vivo detection of substantia nigra and locus coeruleus volume loss in Parkinson's disease using neuromelanin-sensitive MRI: Replication in two cohorts. Hwang KS; Langley J; Tripathi R; Hu XP; Huddleston DE PLoS One; 2023; 18(4):e0282684. PubMed ID: 37053195 [TBL] [Abstract][Full Text] [Related]
10. Relationship between neuromelanin and dopamine terminals within the Parkinson's nigrostriatal system. Martín-Bastida A; Lao-Kaim NP; Roussakis AA; Searle GE; Xing Y; Gunn RN; Schwarz ST; Barker RA; Auer DP; Piccini P Brain; 2019 Jul; 142(7):2023-2036. PubMed ID: 31056699 [TBL] [Abstract][Full Text] [Related]
11. Evaluation of Parkinson disease and Alzheimer disease with the use of neuromelanin MR imaging and (123)I-metaiodobenzylguanidine scintigraphy. Miyoshi F; Ogawa T; Kitao SI; Kitayama M; Shinohara Y; Takasugi M; Fujii S; Kaminou T AJNR Am J Neuroradiol; 2013; 34(11):2113-8. PubMed ID: 23744697 [TBL] [Abstract][Full Text] [Related]
12. Magnetic resonance correlation of iron content with neuromelanin in the substantia nigra of early-stage Parkinson's disease. Reimão S; Ferreira S; Nunes RG; Pita Lobo P; Neutel D; Abreu D; Gonçalves N; Campos J; Ferreira JJ Eur J Neurol; 2016 Feb; 23(2):368-74. PubMed ID: 26518135 [TBL] [Abstract][Full Text] [Related]
13. Increased iron-deposition in lateral-ventral substantia nigra pars compacta: A promising neuroimaging marker for Parkinson's disease. He N; Langley J; Huddleston DE; Chen S; Huang P; Ling H; Yan F; Hu X Neuroimage Clin; 2020; 28():102391. PubMed ID: 32889398 [TBL] [Abstract][Full Text] [Related]
14. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Hansen AK; Knudsen K; Lillethorup TP; Landau AM; Parbo P; Fedorova T; Audrain H; Bender D; Østergaard K; Brooks DJ; Borghammer P Brain; 2016 Jul; 139(Pt 7):2039-49. PubMed ID: 27190023 [TBL] [Abstract][Full Text] [Related]
15. 7 Tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease. Lehéricy S; Bardinet E; Poupon C; Vidailhet M; François C Mov Disord; 2014 Nov; 29(13):1574-81. PubMed ID: 25308960 [TBL] [Abstract][Full Text] [Related]
16. Quantifying changes in nigrosomes using quantitative susceptibility mapping and neuromelanin imaging for the diagnosis of early-stage Parkinson's disease. Takahashi H; Watanabe Y; Tanaka H; Mihara M; Mochizuki H; Liu T; Wang Y; Tomiyama N Br J Radiol; 2018 Jun; 91(1086):20180037. PubMed ID: 29498540 [TBL] [Abstract][Full Text] [Related]
17. Neuromelanin-sensitive magnetic resonance imaging: Possibilities and promises as an imaging biomarker for Parkinson's disease. Yan Y; Zhang M; Ren W; Zheng X; Chang Y Eur J Neurosci; 2024 May; 59(10):2616-2627. PubMed ID: 38441250 [TBL] [Abstract][Full Text] [Related]
18. 3D neuromelanin-sensitive magnetic resonance imaging with semi-automated volume measurement of the substantia nigra pars compacta for diagnosis of Parkinson's disease. Ogisu K; Kudo K; Sasaki M; Sakushima K; Yabe I; Sasaki H; Terae S; Nakanishi M; Shirato H Neuroradiology; 2013 Jun; 55(6):719-24. PubMed ID: 23525598 [TBL] [Abstract][Full Text] [Related]
19. Increased iron in the substantia nigra pars compacta identifies patients with early Parkinson'sdisease: A 3T and 7T MRI study. Alushaj E; Handfield-Jones N; Kuurstra A; Morava A; Menon RS; Owen AM; Sharma M; Khan AR; MacDonald PA Neuroimage Clin; 2024; 41():103577. PubMed ID: 38377722 [TBL] [Abstract][Full Text] [Related]
20. Neuromelanin-sensitive magnetic resonance imaging features of the substantia nigra and locus coeruleus in de novo Parkinson's disease and its phenotypes. Wang J; Li Y; Huang Z; Wan W; Zhang Y; Wang C; Cheng X; Ye F; Liu K; Fei G; Zeng M; Jin L Eur J Neurol; 2018 Jul; 25(7):949-e73. PubMed ID: 29520900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]